Cochrane · systematic review · CD006625
Quetiapine versus other atypical antipsychotics for schizophrenia
Asmal, L, Flegar, SJ, Wang, J, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
35
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 7 · 16.7%Very low 0 · 0%Low 18 · 42.9%Moderate 17 · 40.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
QUETIAPINE versus ARIPIPRAZOLE for schizophrenia
Population: participants with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. General ‐ average endpoint score PANSS total QUETIAPINE vs ARIPIPRAZOLE | no estimate extracted | 4 studies · 297 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mental state: 2. Positive symptoms average endpoint score PANSS positive subscore QUETIAPINE vs ARIPIPRAZOLE | no estimate extracted | 4 studies · 297 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high = poor) QUETIAPINE vs ARIPIPRAZOLE | no estimate extracted | 4 studies · 297 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life: substantial improvement QUETIAPINE vs ARIPIPRAZOLE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: 1. Sedation QUETIAPINE vs ARIPIPRAZOLE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication QUETIAPINE vs ARIPIPRAZOLE | RR 0.67 [0.12, 3.57] | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Adverse effects: 3. Metabolic ‐ weight gain ≥7% of total body weight QUETIAPINE vs ARIPIPRAZOLE | RR 0.52 [0.1, 2.74] | 2 studies · 155 participants | Low Downgraded: risk of bias, imprecision |
QUETIAPINE versus CLOZAPINE ‐ all data short term for schizophrenia
Population: participants with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. General ‐ average endpoint score short term (PANSS total, high = poor) QUETIAPINE vs CLOZAPINE ‐ all data short term | no estimate extracted | 4 studies · 232 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore QUETIAPINE vs CLOZAPINE ‐ all data short term | no estimate extracted | 2 studies · 142 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mental state: 3. Negative symptoms ‐ average endpoint score short term PANSS negative subscore QUETIAPINE vs CLOZAPINE ‐ all data short term | no estimate extracted | 2 studies · 142 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life: substantial improvement QUETIAPINE vs CLOZAPINE ‐ all data short term | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: 1. Sedation QUETIAPINE vs CLOZAPINE ‐ all data short term | RR 0.22 [0.11, 0.47] | 2 studies · 135 participants | Moderate Downgraded: risk of bias, inconsistency |
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication QUETIAPINE vs CLOZAPINE ‐ all data short term | no estimate extracted | 1 study · 28 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: 3. Metabolic ‐ weight gain QUETIAPINE vs CLOZAPINE ‐ all data short term | RR 0.53 [0.25, 1.11] | 2 studies · 135 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
QUETIAPINE versus OLANZAPINE for schizophrenia
Population: participants with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. General ‐ average endpoint score (PANSS total, high = poor) QUETIAPINE vs OLANZAPINE | no estimate extracted | 11 studies · 1486 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore QUETIAPINE vs OLANZAPINE | no estimate extracted | 9 studies · 801 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Mental state: 3. Negative symptoms ‐ endpoint score PANSS negative subscore QUETIAPINE vs OLANZAPINE | no estimate extracted | 9 studies · 801 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Quality of life: general ‐ average change in endpoint score medium term QLS total score QUETIAPINE vs OLANZAPINE | no estimate extracted | 1 study · 286 participants | Moderate Downgraded: risk of bias, inconsistency |
Adverse effects: 1. Sedation QUETIAPINE vs OLANZAPINE | RR 0.98 [0.84, 1.13] | 7 studies · 1615 participants | Moderate Downgraded: risk of bias |
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication QUETIAPINE vs OLANZAPINE | no estimate extracted | 7 studies · 1127 participants | Moderate Downgraded: risk of bias |
Adverse effects: 3. Metabolic ‐ weight significant gain QUETIAPINE vs OLANZAPINE | RR 0.69 [0.51, 0.95] | 7 studies · 1321 participants | Moderate Downgraded: risk of bias |
QUETIAPINE versus PALIPERIDONE for schizophrenia
Population: participants with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. General ‐ average endpoint score PANSS total QUETIAPINE vs PALIPERIDONE | no estimate extracted | 1 study · 319 participants | Moderate Downgraded: imprecision |
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore QUETIAPINE vs PALIPERIDONE | no estimate extracted | 1 study · 319 participants | Moderate Downgraded: imprecision |
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore QUETIAPINE vs PALIPERIDONE | no estimate extracted | 1 study · 319 participants | Moderate Downgraded: imprecision |
Quality of life: substantial improvement QUETIAPINE vs PALIPERIDONE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: 1. Sedation QUETIAPINE vs PALIPERIDONE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: 2. Extrapyramidal effects use of antiparkinson medication QUETIAPINE vs PALIPERIDONE | RR 0.64 [0.45, 0.91] | 1 study · 319 participants | Moderate Downgraded: imprecision |
Adverse effects: 3. Metabolic weight gain ≥7% of total body weight QUETIAPINE vs PALIPERIDONE | RR 2.52 [0.5, 12.78] | 1 study · 319 participants | Moderate Downgraded: imprecision |
QUETIAPINE versus RISPERIDONE for schizophrenia
Population: participants with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. General ‐ average endpoint score PANSS total score QUETIAPINE vs RISPERIDONE | no estimate extracted | 13 studies · 2155 participants | Moderate Downgraded: risk of bias, inconsistency |
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore QUETIAPINE vs RISPERIDONE | no estimate extracted | 11 studies · 1492 participants | Moderate Downgraded: risk of bias, inconsistency |
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore QUETIAPINE vs RISPERIDONE | no estimate extracted | 10 studies · 1367 participants | Low Downgraded: risk of bias, imprecision |
Quality of life: general average endpoint score QLS total score QUETIAPINE vs RISPERIDONE | no estimate extracted | 3 studies · 152 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: 1. Sedation QUETIAPINE vs RISPERIDONE | RR 1.21 [1.06, 1.38] | 8 studies · 2226 participants | Ungraded |
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication QUETIAPINE vs RISPERIDONE | RR 0.5 [0.36, 0.69] | 8 studies · 2163 participants | Moderate Downgraded: risk of bias |
Adverse effects: 3. Metabolic weight gain ≥7% of total body weight QUETIAPINE vs RISPERIDONE | RR 0.96 [0.82, 1.14] | 9 studies · 2070 participants | Moderate Downgraded: risk of bias, imprecision |
QUETIAPINE versus ZIPRASIDONE for schizophrenia
Population: participants with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. General ‐ average endpoint score PANSS total score QUETIAPINE vs ZIPRASIDONE | no estimate extracted | 1 study · 198 participants | Low Downgraded: risk of bias, imprecision |
Mental state: 2. Positive symptoms ‐ average endpoint score medium term PANSS positive subscore QUETIAPINE vs ZIPRASIDONE | no estimate extracted | 1 study · 198 participants | Low Downgraded: risk of bias, imprecision |
Mental state: 3. Negative symptoms ‐ average endpoint score medium term PANSS negative subscore QUETIAPINE vs ZIPRASIDONE | no estimate extracted | 1 study · 198 participants | Low Downgraded: risk of bias, imprecision |
Quality of life: substantial improvement QUETIAPINE vs ZIPRASIDONE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: 1. Sedation QUETIAPINE vs ZIPRASIDONE | RR 1.36 [1.03, 1.81] | 2 studies · 754 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication QUETIAPINE vs ZIPRASIDONE | RR 0.43 [0.2, 0.93] | 1 study · 522 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: 3. Metabolic weight gain ≥7% of total body weight QUETIAPINE vs ZIPRASIDONE | RR 2.22 [1.35, 3.63] | 2 studies · 754 participants | Moderate Downgraded: risk of bias |